Who we are

We are ArcVance, a spin-off from Nanyang Technological University (NTU) dedicated to transforming the way blood is processed for early cancer detection. Our journey began with a simple but urgent mission: to preserve the integrity of rare cell-free biomarkers that are often lost before they can be analyzed.

Powered by our patented ExoArc® microfluidic platform, we deliver ultra-pure plasma at the point of care, eliminating cellular noise and enabling earlier, more accurate disease detection. Our team blends decades of expertise in microfluidics, diagnostics, and medical device commercialization, united by a vision to make high quality biomarker analysis a standard part of precision medicine worldwide.